Retsevmo

Waarvoor het wordt gebruikt

Retsevmo as monotherapy is indicated for the treatment of adults with:  advanced RET fusion positive non small cell lung cancer (NSCLC) not previously treated with a RET inhibitor advanced RET fusion positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1) Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with: advanced RET fusion positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate) advanced RET mutant medullary thyroid cancer (MTC)